Menu Close

News

4.29.22 – SHINGRIX is a vaccine indicated for the prevention of herpes zoster (HZ) (shingles): in adults aged 50 years and older. in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

 

  • Wednesday – May 11th, 2022 @ 12:15 PM CDT – Implementing Shingrix In Patients 50 years of age or older – Stephen Tyring, MD

  • Thursday – May 19th, 2022 @ 11:15 AM CDT – Implementing Shingrix in Patients 50 years of age or older – Sean Lang, PhD

  • Wednesday – May 25th, 2022 @ 2:15 PM CDT – Implementing Shingrix in IC Patients 18 years of age or older – Carrie Koenigsfeld, PharmD

  • Wednesday – June 8th, 2022 @ 11:15 AM CDT – Implementing Shingrix in IC Patients 18 years of age or older – Carrie Koenigsfeld, PharmD
  • Thursday – June 16th, 2022 @ 12:15 PM CDT – Implementing Shingrix in Patients 50 years of age or older – Carrie Koenigsfeld, PharmD
  • Tuesday – June 21st, 2022 @ 11:15 AM CDT – Implementing Shingrix in Patients 50 years of age or older – Mary Hayney – Pharm

4.13.22 – Sanofi Announces Remaining Menactra Stock will be Depleted in the US over the Next Several Months To Prioritze MenQuadfi

Sanofi is anticipating that the remaining Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] stock will be depleted in the US over the next several months. As such, Menactra will be removed from all future Sanofi US contracts and will be unavailable for purchase after the final doses are depleted.

Sanofi will be prioritizing the production of MenQuadfi® [Meningococcal (Groups A, C, Y, W) Conjugate Vaccine] in the US moving forward. To learn more about this product transition, please see the customer letter attached.

4.7.22 – Moderna Releases Fact Sheet For Healthcare Providers Administiring SPIKEVAX Boosters

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, MODERNA COVID-19 VACCINE, for active immunization to prevent COVID-19 in individuals 18 years of age and older. 

 

There are 2 presentations of Moderna COVID-19 Vaccine authorized for use in individuals 18 years of age and older. Both presentations are supplied in multiple-dose vials and can be used for a booster dose. 

 

SPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by ModernaTX, Inc. that is indicated for active immunization to prevent COVID-19 in individuals 18 years of age and older. 

The volume of a booster dose of Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA) depends on the presentation:

 

  • Multiple-dose vial of Moderna COVID-19 Vaccine with a dark blue cap and a label with a purple border – Booster Dose is 0.5 mL 


  • Multiple-dose vial of Moderna COVID-19 Vaccine with a red cap and a label with a light blue border – Booster Dose is 0.25 mL 

  • Multiple-dose vial of SPIKEVAX (COVID-19 Vaccine, mRNA) with a red cap and a label with a light blue border – Booster Dose is 0.25 mL

3.21.22 – Sanofi Announces New Presentation and Change in Formulation for Quadracel

Quadracel vero formulation has been approved by the FDA for active immunization for the prevention of diphtheria, tetanus, and pertussis in a pre-filled syringe. Quadracel formulated with Vero cell derived IPV retains the same dosing schedule, indication, safety, immunogenicity data and pricing as the Quadracel vaccine formulation you use currently. Both formulations of Quadracel can be used to complete the DTaP series.

 

3.21.22 – Join GSK Professionals For a  Webinar Program To Provide Disease Education For Meningococcal Serogroup B 

The purpose of the program is to provide disease education on meningococcal serogroup B,  including meningococcal B vaccination and the Advisory Committee on Immunization. Practices (ACIP) recommendations.

Tuesday – April 19th, 2022 @ 2:15 PM CDT – Disease Education w/ Dr. Sherman Alter

Wednesday – April 20th, 2022 @ 12:15 PM CDT – Disease Education w. Dr. Jitendrakumer Modi

Tuesday – April 26th, 2022 @ 11:15 AM CDT – Disease Education w/ Dr. Jon Dvorak

Wednesday – April 27th, 2022 @ 2:15 PM CDT – Disease Education w/ Dr. Anita Chandra-Puri

Wednesday – May 11th, 2022 @ 2:15 CDT – Disease Education w/ Dr. Joseph Domachowske

Thursday – May 12th, 2022 @ 11:15 AM CDT – Disease Education w/ Dr. Sherman Alter

Monday – May 16th, 2022 @  2:15 PM CDT – Disease Education w/ Dr. Jitendrakumer Modi

Tuesday – May 17th, 2022 @ 2:15 PM CDT – Disease Education w/ Dr. Joseph Domachowske

Tuesday – May 24th, 2022 @ 11:15 AM CDT – Disease Education w/ Dr. Dave Smeltzer 

Wednesday – May 25th, 2022 @ 2:15 PM CDT – Disease Education w/ Dr. Anita Chandri-Puri

Tuesday – June 7th, 2022 @ 12:15 PM CDT – Disease Education w/ Dr. Sherman Alter 

Wednesday – June 8th, 2022 @ 11:15 AM CDT – Disease Education w/ Dr. Jon Dvorak

Wednesday – June 15, 2022 @ 12:15 PM CDT – Disease Education w/ Dr. Jitendrakumar Modi 

Tuesday – June 21st, 2022 @ 12:15 PM CDT – Disease Education w/ Dr. Dave Smeltzer 

Thursday, June 30th, 2022 @ 11:15 AM CDT – Disease Education w/ Dr. Jon Dvorak 

3/17.22 – A new presentation for Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed, and Inactivated Poliovirus Vaccine) to be available.  

A new presentation and formulation of Quadracel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, and Inactivated Poliovirus Vaccine). Quadracel will soon be available to order in a pre-filled syringe made without natural rubber latex. We also changed the source of Inactivated Polio Virus (IPV) antigen from MCR-5-derived IPV (mIPV) to IPV derived from vero cells (vIPV), which aligns with that contained in Sanofi Pasteur’s single entity IPV vaccine. Quadracel formulated with Vero cell derived IPV retains the same dosing schedule, indication, safety, immunogenicity data and pricing as the Quadracel vaccine formulation you use currently.

 

Quadracel is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

3.14.22 – GSK’s MMR Vaccine PRIORIX: Overview

GSK’s MMR vaccine (PRIORIX) o First licensed in Germany in 1997; approved in > 100 countries outside US and over 400 million doses distributed worldwide The goal of GSK’s MMR development program is to bring a vaccine to the US market that: 

1. fulfills the ACIP recommendations for measles, mumps, and rubella vaccination [CDC, 2013] 

2. demonstrates immunologic non-inferiority and comparable safety to the currently licensed US vaccine, M-M-R II (Merck & Co., Inc) 

3. can be administered interchangeably to individuals who received a previous vaccination with M-M-R II or ProQUAD

Indication: • PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals aged 12 months and older. Dose and Schedule: • PRIORIX is administered as an approximately 0.5-mL dose by subcutaneous injection according to the following schedule. –The first dose is administered at 12 to 15 months of age. A second dose is administered at 4 to 6 years of age. • The second dose may be administered prior to 4 years of age, provided there is a minimum interval of 4 weeks between the doses of live measles, mumps, and rubella vaccine. • The second dose may also be administered at 7 years and older.